Diligence memo · auto-generated · as of July 3, 2026
858 Therapeutics, Inc.
858 Therapeutics, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
858 Therapeutics, Inc. operates in Pharmaceuticals, based in SAN DIEGO.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
858 Therapeutics, Inc. has raised $65M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $25M on 2024-06-26.
Most recent recorded round closed around 2024-06-26.
Valuation (modeled)modeled
Provath models 858 Therapeutics, Inc. at approximately $177M (range $53M–$318M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.36× the median modeled value of Series B Pharmaceuticals companies in 2022–2024 (51 peers) — value vs value, same stage and era. Within the normal band (136% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 26 months.
Last raise 2.0 yr ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round stepped up 1.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 85% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 66% of those peers.
Closest niche peers: MedAvail Holdings, Inc., Revalesio Corp, Kinaset Therapeutics, Inc., Venatorx Pharmaceuticals, Inc., Cxl Ophthalmics, Inc..
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.